Fingerprint
Dive into the research topics of 'The VIOXX in prostate cancer prevention study: Cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
The VIOXX in prostate cancer prevention study: Cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups
Janet Van Adelsberg, Peter Gann, Amy T. Ko, Jan Erik Damber, Christopher Logothetis, Michael Marberger, Bernd J. Schmitz-Drager, Andrea Tubaro, Celia J. Harms, Claus Roehrborn
Research output: Contribution to journal › Article › peer-review
26
Scopus
citations